[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lung-fibrosis-interstitial\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lung-fibrosis-interstitial":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,54,86],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100644762","remote-evaluation-and-surveillance-of-patients-with-interstitial-lung-disease-transforming-ild-care-delivery-with-remote-monitoring-100644762",false,"NCT07673237","Remote Evaluation and Surveillance of Patients With Interstitial Lung Disease: Transforming ILD Care Delivery With Remote Monitoring","RESPOND-ILD","Inclusion Criteria:\n\n* age 18 or older\n* English or Spanish speaking\n* have a UCSF diagnosis of one of the major ILD subtypes seen in the ILD Clinic (Idiopathic Pulmonary Fibrosis, Chronic Hypersensitivity Pneumonitis, Connective-tissue disease related ILD, Sarcoidosis, Familial Fibrosis). Languages are limited to those for which both device instructional materials and user support are available (written and video). The ILD diagnosis will be based on multidisciplinary conference review, which is the diagnostic gold standard. We have restricted the ILD subtypes to those for which there is efficacy data for RPM or comparable clinical trajectories, and subtypes that account for \\>10% of the ILD diagnoses seen at UCSF.\n\nExclusion Criteria:\n\n* Patients who are unable provide informed consent for any reason or are acutely ill.","ALL","18 Years",{"count":19,"type":20},200,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this interventional study is to identify which combination of remote monitoring devices (e.g. home spirometry, pulse oximetry, scale, ePROs) is the most feasible (as defined by adherence, retention, and data completeness) and acceptable when used for the detection of clinically significant Interstitial Lung Disease events.",[26,27,28],"Fibrotic Interstitial Lung Disease","IPF and PPF","Lung Fibrosis Interstitial",[30,31,32,33,34,35,36,37,38,39,40],"Interstitial lung disease","pulmonary fibrosis","idiopathic pulmonary fibrosis","progressive pulmonary fibrosis","Remote patient monitoring","Digital health","Telemonitoring","Home monitoring","Pragmatic study design","Real-world monitoring","Decentralized clinical trial","NOT_YET_RECRUITING","2026-06-22",{"date":44,"type":45},"2026-06-29","ACTUAL",{"date":47,"type":20},"2026-08-01",{"date":49,"type":20},"2028-08-01",{"name":51,"class":52},"University of California, San Francisco","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":21,"phases":64,"briefSummary":65,"conditions":66,"keywords":67,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":85},"100628117","evaluation-of-the-pulmonary-fibrosis-learning-and-self-management-programme-filip-100628117","NCT07457463","Evaluation of the Pulmonary Fibrosis Learning and Self-management Programme (FILIP)","Self-efficacy and Well-being of Patients With Fibrotic Interstitial Lung Disease - an Observational Study","FILIP","Inclusion criteria are:\n\n* Diagnosis of a FILD as major indication for pulmonary rehabilitation (for Berner Reha Zentrum only)\n* Enrolled in Idiopathic interstitial Pneumonia (IIP) cohort study (Nr. 246\u002F15 \u002F PB\\_2016-01524) and agreed to further use of data for further research purpose (for Inselspital only)\n* Age ≥ 18 years\n* Written informed consent\n\nExclusion criteria are:\n\n* Cognitive inability or insufficient knowledge of project language (German) to follow informed consent or study procedures\n* Sarcoidosis",{"count":63,"type":20},80,[23],"The goal of this observational study is to evaluate the feasibility and acceptability of a newly developed digital education and self-management program for people with fibrotic interstitial lung diseases (FILD) during inpatient pulmonary rehabilitation and outpatient interstitial lung disease (ILD) care. The study also explores whether participation in the program is associated with changes in health-related outcomes.\n\nThe main questions this study aims to answer are:\n\n* Is the digital education and self-management program acceptable, useful, and practical for patients with FILD?\n* Is it feasible to recruit and retain patients and to collect outcome data for a future larger effectiveness study?\n* Do patients who participate in the program show differences in health-related outcomes compared with patients treated before the program was implemented?\n\nPatients who consent to participate during the implementation phase will be offered access to the digital education and self-management program. Their outcomes will be compared with those of a historical cohort of patients who received usual care before the program was introduced.\n\nParticipants will:\n\n* Use a web-based digital education and self-management program with multiple e-learning modules tailored to individual needs and preferences\n* Access the program via smartphone, tablet, or computer during inpatient rehabilitation or outpatient care\n* Discuss questions related to the program content with healthcare professionals during routine rehabilitation sessions or clinic visits\n* Complete questionnaires about their experience with the program and their health-related outcomes",[28],[68,69,70,71,72,73,74],"self-management","patient education","self-efficacy","blended learning","lung fibrosis","ILD","digital patient information","RECRUITING","2026-03-03",{"date":78,"type":45},"2026-03-09",{"date":80,"type":45},"2025-10-07",{"date":82,"type":20},"2027-08",{"name":84,"class":52},"Insel Gruppe AG, University Hospital Bern",2,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":95,"phases":4,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":53},"100586578","proof-of-concept-study-on-the-efficacy-of-inhalatory-targeted-imatinib-nanoformulations-in-pulmonary-hypertension-and-post-inflammatory-fibrosis-100586578","NCT06917196","PROOF OF CONCEPT STUDY ON THE EFFICACY OF INHALATORY TARGETED IMATINIB NANOFORMULATIONS IN PULMONARY HYPERTENSION AND POST-INFLAMMATORY FIBROSIS.","PROMPTLY","Inclusion Criteria:\n\n* Patients aged ≥ 18 years diagnosed with fibrosing lung disease, obliterative bronchiolitis, or PAH, who are candidates for or have undergone lung transplantation.\n* Obtaining informed consent for all patients enrolled prospectively and all those enrolled retrospectively at their first clinical occurrence at our center.\n\nExclusion Criteria:\n\n* Suspected or confirmed diagnosis of pulmonary neoplastic disease.",{"count":94,"type":20},16,"OBSERVATIONAL","The PROMPTLY study is a proof-of-concept research project evaluating the efficacy of XHALIP, an innovative inhalable formulation of Imatinib, in treating pulmonary arterial hypertension (PAH) and post-inflammatory fibrosing lung diseases (LFD).\n\nMain Objective To demonstrate the ability of XHALIP to improve the prognosis of PAH and LFD by reducing pulmonary fibrosis and vascular remodeling.\n\nKey Research Questions Is XHALIP effectively absorbed by pathological lung cells? Does it have a beneficial biological effect on cell proliferation and extracellular matrix deposition? Study Plan Preclinical phase: In vitro tests on cells obtained from patients with PAH and LFD.\n\nAbsorption and distribution analysis: In vitro lung tissue models to assess drug penetration and effectiveness.\n\nBiological activity assessment: Evaluating XHALIP's ability to inhibit epithelial-mesenchymal transition and cell proliferation.\n\nParticipants Patients aged ≥ 18 years diagnosed with PAH or LFD, either candidates for or recipients of lung transplantation.\n\nBiological samples (bronchoalveolar lavage and explanted lung tissues). Methodology Confocal microscopy and flow cytometry to analyze absorption. RT-PCR and Western Blot to assess biological efficacy. Alveolo-capillary models to test drug release and distribution. The study aims to translate preclinical findings into a potential future clinical trial for the development of XHALIP as a novel inhalation-based therapeutic strategy for rare lung diseases.",[98,28],"Pulmonary Arterial Hypertension (PAH)",[100,101,102,103,104,105],"PAH","LFD","Pulmonary arterial hypertension","lung fibrosis desease","XHALIP","imatinib","2025-03-31",{"date":108,"type":45},"2025-04-08",{"date":110,"type":45},"2023-12-04",{"date":112,"type":20},"2026-06-04",{"name":114,"class":52},"Fondazione IRCCS Policlinico San Matteo di Pavia"]